Klin Farmakol Farm. 2008;22(2):68-71

Biological treatment in dermathology

Martin Tichý, Dagmar Ditrichová
Klinika chorob kožních a pohlavních LF UP a FN Olomouc

Biologics are genetically engineered drugs used for systemic application and belong to the group of selective immunosuppressive agents. Their significant therapeutic efficacy has been demonstrated in numerous immune mediated disorders. Currently, biologics are only indicated for the treatment of severe forms of psoriasis in dermatology. Four preparations are registered for the treatment of psoriasis in the Czech Republic – efalizumab, etanercept, infliximab and adalimumab.

Keywords: Key words: biologics, dermatological indications, efalizumab, etanercept, infliximab, adalimumab.

Published: January 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tichý M, Ditrichová D. Biological treatment in dermathology. Klin Farmakol Farm. 2008;22(2):68-71.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Benáková N, Štork J. Léčba psoriázy biologiky. Konsensuální doporučené postupy České dermatovenerologické společnosti ČLS JEP 2006. Čes Slov Derm 2006; 81 (4): 1-11.
    2. Krueger G, Ellis CN. Psoriasis - Recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005; 53 (supl. 1): 94-100. Go to original source... Go to PubMed...
    3. Tichý M, Ditrichová D. Biologika v léčbě těžkých forem psoriázy. Dermatolog praxi 2007; 1: 19-21.
    4. Ettehadi P, Greaves MW, Wallach D, et al. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146-151. Go to original source... Go to PubMed...
    5. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004-2013. Go to original source... Go to PubMed...
    6. Menter A, Gordon K, Carey W, et al, for the Efalizumab Study Group. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141: 31-38. Go to original source... Go to PubMed...
    7. Gordon KB, Papp KA, Hamilton TK, et al, for the Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis. JAMA 2003; 290: 3073-3080. Go to original source... Go to PubMed...
    8. Culy ChR, Keating MG. Etanercept. An updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile arthritis. Drugs 2002; 62: 2493-2537. Go to original source... Go to PubMed...
    9. Šedová L, Štolfa J. Biologická léčba psoriatické artritidy. Dermatolog praxi 2007; 1: 31-35.
    10. Nestorov I, Zitnik R, DeVries T, Nakanishi AM, Wang A, Banfield C. Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. Br J Clin Pharmacol 2006; 62: 435-445. Go to original source... Go to PubMed...
    11. Leonardi CL, Powers JL, Matheson RT, et al, for the Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022. Go to original source... Go to PubMed...
    12. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-1632. Go to original source... Go to PubMed...
    13. Khana D, McMahon M, Furst DE. Safety of tumour necrosis factor - alpha antagonists. Drug Saf 2004; 27: 307-324. Go to original source... Go to PubMed...
    14. Calabrese LH. Molecular differences in anticytokine therapies. Clin Exp Rheumatol 2003; 21: 241-248. Go to PubMed...
    15. Gottlieb AB, Chaudhari U, Mulcahy LD, et al. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003; 48: 829-835. Go to original source... Go to PubMed...
    16. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-542. Go to original source... Go to PubMed...
    17. Chew A-L, Bennett A, Smith CH, et al. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br J Dermatol 2004; 151: 492-496. Go to original source... Go to PubMed...
    18. Gordon KB, Langley RG, Leonardi C, et al. Clinical Response to Adalimumab Treatment in Patients with Moderate to Severe Psoriasis: Double-Blind, Randomized Controlled Trial and OpenLabel Extension Study. J Am Acad Dermatol 2006; 55 (4): 598-606. Go to original source... Go to PubMed...
    19. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient membership survey. Arch Dermatol 2001; 137: 280-284. Go to PubMed...
    20. Lewis V, Finlay AY. Ten years experience of the Dermatology Life Quality Index (DLQI). J Invest Dermatol Symp Proc 2004; 9: 169-180. Go to original source... Go to PubMed...
    21. Lewis-Jones MS, Finlay AY. The Children´s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995; 132: 942-949. Go to original source... Go to PubMed...
    22. Ogilvie AL, Antoni C, Dechant C, et al. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001; 144: 587-589. Go to original source... Go to PubMed...
    23. Rongioletti F, Borenstein M, Kirsner R, et al. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab. J Dermatolog Treat 2003; 14: 222-225. Go to original source... Go to PubMed...
    24. Newland MR, Weinstein A, Kerdel F. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol 2002; 41: 449-452. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.